본문 바로가기 주메뉴 바로가기
  • HOME
  • R&D
  • Pipeline
  • CAR-T CELLS

CAR-T Cells

INTRODUCTION
  • It is an anti-cancer immune cell therapy that separates only T cells from the immune cells of patients and introduces CAR, cultivates them, and injects them back into the patient to treat cancer.
  • Cancer cells inhibit the expression of MHCs, which are essential for T cells to recognize antigens, in order to avoid the immune system of the human body. However, CAR-T cells are anti-cancer immune cell treatments suitable for safety and targeted treatment by allowing direct recognition of cancer cells without the help of MHC.
rnd_02_02 사진
MECHANISM
  • Production stable and efficient CAR-T using lentivirus.
  • rnd_dt_01
  • Improved CAR-T production using 3rd generation lentivirus.
  • rnd_dt_02
  • Targeting mesothelin (MSLN) to attack solid tumor.
  • rnd_dt_03
WHY? GCC-CAR-T
  • Existing CAR-T immunotherapy applies to hematologic cancer, but GCC CAR-T targets solid tumor.
  • It is improved functionally using 3rd generation CAR lentivirus.
  • rnd_dt_01
ADVANTAGES
  • MSLN expression is low level in normal tissues but is highly expressed in several solid tumors. Due to such characteristics, it is used as an ideal target for CAR-T cell therapy in MSLN expressing solid tumors.
  • MSLN-CAR-T that we developed showed very efficient anti-tumor effects in the orthotopic pancreatic mouse model.
  • rnd_dt_01